Home » Topics » BioWorld Science

BioWorld Science
RSS

Ozanimod demonstrates early histologic improvement in patients with active CD

Oct. 28, 2019

Replimune begins phase I study of RP-2 alone and with Opdivo in advanced solid tumors

Oct. 28, 2019

New ultrasensitive tau seed amplification assay for detection and subtyping of 4-repeat tauopathies

Oct. 28, 2019

FDA clears IND for phase I trial of SQZ-PBMC-HPV

Oct. 25, 2019

European Commission approves Xospata for relapsed or refractory FLT3 mutation-positive AML

Oct. 25, 2019

FDA approves Baxdela for community-acquired bacterial pneumonia

Oct. 25, 2019

NIAID awards contract to UAB to study Bexsero for gonorrhea prevention

Oct. 25, 2019

New phase I trial investigates MB-108 in recurrent glioblastoma multiforme

Oct. 25, 2019

Syros reports new data from phase II trial of SY-1425 in newly diagnosed unfit AML

Oct. 25, 2019

Japan Tobacco describes new SLC5A1 inhibitors

Oct. 25, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...